Navigation Links
Abaxis Reports Financial Performance With Record Sales for the Third Quarter of Fiscal 2011

s and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2010 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(in thousands, except per share data)(Unaudited)Three Months EndedNine Months EndedDecember 31,December 31,2010200920102009Revenues




90,892Cost of revenues




37,590Gross profit




53,302Operating expenses:Research and development




8,002Sales and marketing




21,428General and administrative



SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
2. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
3. Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
4. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
5. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
7. Abaxis to Report Second Quarter Fiscal 2011 Financial Results Tuesday, October 26, 2010
8. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
9. Abaxis, Inc. to Present at Stephens Fall Investment Conference
10. Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus
11. Abaxis to Report Third Quarter Fiscal 2011 Financial Results Thursday, January 27, 2011
Post Your Comments:
(Date:10/8/2015)... 8, 2015  Clariant, a world leader in specialty chemicals, ... in Belen, New Mexico , has achieved ... desiccant canisters and packets and other container-closure ... is the second Clariant site – the first in ... ISO 15378:2011 standards, following only the Clariant manufacturing facility in ...
(Date:10/8/2015)... Oct. 08 2015 ... "Global API Market Outlook 2020" report ... has announced the addition of the "Global ... offering. --> Research and Markets ( ... "Global API Market Outlook 2020" report ...
(Date:10/8/2015)... The Pharmaceutical Care Management Association (PCMA) today announced the ... as the association,s new Vice President of State ... Mr. Kipper was twice appointed Commissioner of the Nevada ... in charge of the Office of Health Insurance for ... the state,s Office of Group Benefits. He also served ...
Breaking Medicine Technology:
... Growing Childhood Condition, WASHINGTON, May 22, 2007 ... regarding pediatric patients,with gastroesophageal reflux disease (GERD) ... Digestive Disease Week meeting held at the,Washington ... further support AstraZeneca's,commitment to research in the ...
... According to,New Data Presented at Digestive Disease Week ... announced today that,new data presented at Digestive Disease ... Crohn's disease,patients treated with Cimzia (certolizumab pegol), the ... called PRECiSE 3 (P3), is a long-term open ...
Cached Medicine Technology:
(Date:10/9/2015)... Schaumburg,IL (PRWEB) , ... October 09, 2015 , ... ... provider, is pleased to announce it will sponsor the upcoming Cisco Georgia Partner ... Pavilion Sports Complex on the campus of Georgia Tech, in Atlanta, Georgia. , ...
(Date:10/9/2015)... ... 2015 , ... In the heat of World War II and during the ... very brave group of men were formed to disarm these bombs and protect the ... rapid disposal of unexploded bombs is of the highest importance. The work of ...
(Date:10/8/2015)... ... October 08, 2015 , ... The ... its 15-year anniversary and reveal a new, patient-centered messaging campaign at its upcoming ... The conference theme and campaign tagline, “Smarter Research to Unlock Cures,” supports numerous ...
(Date:10/8/2015)... CA (PRWEB) , ... October 08, 2015 , ... ... Marketing/PR, (510) 632-9525 ext. 130 , Oakland Zoo Hosts Weekend of Happy Halloween ... new overnight experience called, Family Sundown SPOOKfari . The program is designed ...
(Date:10/8/2015)... Philadelphia, PA (PRWEB) , ... October 08, 2015 ... ... of the Philadelphia 100® for the fifth consecutive year. The Philadelphia 100® has ... which is run by the Wharton Small Business Development Center, The Entrepreneurs' Forum ...
Breaking Medicine News(10 mins):
... ... Corporation (NYSE:ITT) announced today that its file inspection application, PuriFile®, has successfully integrated ... for government customers. , ... Rome, N.Y. (PRWEB) August 27, 2009 -- ITT Corporation (NYSE:ITT) ...
... , WILMINGTON, Del., Aug. 27 As part of ... (NYSE: AZN ) is bringing The Bipolar Journey: ... across America. Those who have been touched by bipolar depression -- ... a nearby exhibit site and learn more about living with this ...
... , PITTSBURGH, Aug. 27 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% ... Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The ... to be approved by the U.S. Food and Drug Administration ...
... CUPERTINO, Calif., Aug. 27 DURECT Corporation (Nasdaq: ... long term excipient supply agreement with respect to REMOXY(R) with ... stipulates the terms and conditions under which DURECT will supply ... percentage mark-up, two key excipients used in the manufacture of ...
... Ten Big Brothers Big Sisters agencies will receive the ... parents as partners" to help children improve their odds for ... is the nation,s largest donor-supported volunteer mentoring network with nearly ... parents, with a focus on breaking negative cycles. Big ...
... , , , ... Inc . (Nasdaq: CPIX ), a specialty pharmaceutical company ... second quarter 2009 financial results. , , "Our ... most significant events in the Company,s history--receipt of Food and Drug ...
Cached Medicine News:
... AirLife Brand Misty Max 10 Nebulizer W/ ... advanced jet design for fast treatment times ... tighter distribution (higher percentage of respirable particles) ... Misty Max 10™ disposable nebulizers deliver fast ...
... Nebulizer Disposable Prefilled 28%-100% FIO 2 500ML ... prefilled nebulizers provide unmatched performance and ease of ... aerosols adjustable from 28% to 100% FIO 2 ... sterile water for inhalation, USP; 0.45% sodium chloride ...
... Nebulizer Disposable Prefilled 28%-100% FIO 2 ... ,Our prefilled nebulizers provide unmatched performance ... and cool high-output aerosols adjustable from 28% to ... selection of solutions: sterile water for inhalation, USP; ...
... 2 500ML 0.9% Sodium Chloride ... unmatched performance and ease of use. You can ... 28% to 100% FIO 2 . We offer ... inhalation, USP; 0.45% sodium chloride inhalation, USP; and ...
Medicine Products: